In addition, as it has been suggested that there are distinct differences in clinical characteristics of breast or ovarian cancer [13,14,15] and in the spectrum of BRCA1/2 variants between non-Europeans and Europeans [10,11,16,17], questions arise about whether the cancer risk by pathogenic or likely pathogenic variants (PLPVs) in BRCA1/2 estimated based on Europeans can be used in non-European populations. This evidence concerns the gene BRCA1 and ovarian carcinoma.